EXHIBIT M

LSI USA '22 | EMERGING MEDTECH SUMMIT

Embody is the soft tissue healing company.

- Historical focus had been on "mechanical strength" augmentation, not biological.

  Formative cadaveric or synthetic products lack appropriate ***combination of biologic collagen chemistry, microarchitecture & structural integrity for tendon repair***

- Funded by DARPA and AFWERX with $22 million to develop collagen-based implants for soft tissue repair and augmentation.
- Launched Tapestry Biointegrative Implant in 2021. Launching TAPESTRY RC in arthroscopic RC repair in Q2.
- Launching MICROBRAID in Q1 2023.

TAPESTRY® Biointegrative Implant TAPESTRY® RC MICROBRAID™

EMBODY

Platforms Extend to All Major Sports Med Segments



Source: BioMed GPS SmartTrack, 2019

An Exceptional Team to Deliver Commercial Results

Jeff Conroy
CEO

Tim Meyers
CFO

Rob Brown
CCO

Christy Nelson
VP, Manufacturing

John Rizzo
VP, Sales

Brianna Schehr
Dir, Clinical & Regulatory

Caitlin Harclerode
Dir, Product Marketing

Vicki Phillos
Dir, Commercial Ops

Matt Havener
Dir, Product Development

Clinical Advisors and Faculty

Shoulder

- *Kevin Bonner, MD*, Jordan-Young Institute
- *Brandon Bryant, MD*, Inova Sports Medicine, Washington NFL Team & Nationals Team Surgeon
- *Nick Sgaglione, MD*, Northwell Health
- *Louis McIntyre, MD*, Northwell Health
- *Sean Churchill, MD*, Aurora Health Center
- *Chris Jones, MD*, Colorado Springs Orthopedic
- *Sam Harmsen, MD*, TOCA
- *Kyle McClintock, MD*, Sutter Health, CORE Inst.
- *Amit Nathani, MD*, The Spine & Orthopedic Ctr CA

Hip

- *W. Kelton Vasileff, MD*, Ohio State University Medical Ctr
- *John Ryan, MD*, Ohio State University Medical Ctr

Foot & Ankle

- *Sam Adams, MD*, Duke Orthopedics, Head of F & A Research
- *Sheldon Lin, MD*, Rutgers-NJMS, Head of Orthopedic Research
- *Bill Simon, DPM*, Atlantic Foot & Ankle Center
- *Alan Ng, DPM*, FACFAS Denver, CO
- *Eric Giza, MD*, UC Davis
- *Kent Ellington, MD*, OrthoCarolina, NC

Sports Med (Knee)

- *Greg DiFelice, MD*, Hospital for Special Surgery
- *Kevin Bonner, MD*, Jordan-Young Institute

Orthopedic Research

- *Steven Arnoczky, DVM*, Michigan State University

HSS · Premier Orthopaedics · Jordan Young Institute Orthopedic Surgery & Sports Medicine · Duke Orthopaedic Surgery, Duke University School of Medicine · INOVA Sports Medicine

TAPESTRY Optimized Physio-Chemistry for Tendon

The TAPESTRY Biointegrative Implant is a bioengineered implant combining Type 1 Bovine collagen chemistry with a highly aligned & highly porous architecture

- Bioengineered micro-architecture & chemistry specifically designed for tendon repair.
  - Unaligned outer surface for isotropic suture retention strength and structural integrity
  - Highly aligned and consistent microarchitecture mimics native tendon
- Highly porous (>90%) to encourage cell and fluid infiltration
- Broad range of sizes & shapes: 20x30mm up to 70x50mm
- Room Temperature Storage, no refrigeration required
- FDA Clearance October 9, 2020 (K201572)
  - Indicated for the management and protection of tendon injuries ...."*Preclinical studies of TAPESTRY® showed dense collagenous fibrous connective tissue ingrowth into and around the scaffolding*"



1. Lin et. al., Biomaterials 2014
2. TAPESTRY IFU.

TAPESTRY Mechanism of Action

A **collagen-based co-polymer with highly aligned, cell infiltration friendly microstructure** and controlled degradation profile, tailored fiber diameter, specific porosity/void up **100 µm.**

Patented Collagen Co-polymer

Patented Physio-Chemistry

Bioengineered 3D Micro-architecture

Unique Cellular Micro-environment





Early cell infiltration, attachment, and elongation

New collagen deposition and biointegration at 4wks

Incorporation into the native tissue 26wks

Induction of new, dense, collagenous tendon-like tissue @ 26 – 52wks

T = Tendon
I = TAPESTRY Implant
* = Tendon-Implant Interface

Maghdouri-White et *al.*, 2020

Superior Micro-Architecture for Tendon Healing[1]

TAPESTRY



Reconstituted Collagen



Acellular Dermis



TAPESTRY is significantly more porous and ordered than conventional biomaterials and is an analog to native tendon structure

1. *Embody data on file*

Ultrasound Imaging at 6-Months



KEY FINDINGS

- Tendon thickness: 0.5 cm
- Tendon width: 3.1 cm
- Tendon echotexture: "Normal fibrillar echogenic tendon architecture without evidence of tendinosis."
- Tendon integrity: "Intact"
- Other: "The collagen scaffold is not directly visualized suggesting complete integration or resorption. No anterior glenohumeral joint effusion or distention
- of the subcoracoid bursa."

Conclusion: "Intact subscapularis tendon without evidence of tendinosis or tear."

- Sunbscapularis Patient Series (n=5-15), with plans to expand to multi-center study & registry creation. Patients undergoing anatomic shoulder arthroplasty for primary glenohumeral osteoarthritis.
- 6 month post-op Ultrasound Evaluation w/fellowship-trained MSK radiologist (SSc integrity, tendon thickness, collagen architecture, graft integration)
- No complications observed (no aseptic bursitis, infection, SSc ruptures).

Unparalleled Clinical Applications to Date...







TAPESTRY® RC

Instrumented Delivery & Fixation Solution

TAPESTRY RCR Addressable Procedures



- 510(k) Clearance for broad indication of **"Management and protection of tendon injuries"**
- Grade III partial and Full Thickness tears = 80% of mkt
- Severe Tendinosis, failed conservative treatment

Source: SmartTRAK GPS, Embody RCR Study

TAPESTRY RC System: Streamlined Delivery & Fixation

Simple. Controlled. Versatile. Efficient.

Implant Delivery

- Simple & low-cost design.
- Introducer pre-loaded with implant
  - Sizes: 20x30mm, 30x30mm, 40x30mm
- Highly controlled, single handed placement & operation
- Accommodates surgeon approach preference (lateral or anterior delivery).

Implant Fixation

- Pre-loaded, multiple (2) anchor delivery in single pass
  - PDO resorbable material
  - Optimized design for both tendon and bone fixation
- Visualization and protection of anchor during delivery
- Simple, quick, single-handed & reproducible operation

MICROBRAID®

Collagen Suture

High Strength Biointegrative Suture

MICROBRAID Overview

Advantages over conventional High-Strength Orthopedic Sutures:

- Biologic: Biostimulative collagen stimulates angiogenesis, promotes new collagen formation and bio-integration.
- Balanced: Controlled degradation of collagen as remodeling occurs, retaining strength of UHMWPE fibers
- Biocompatible: Novel cross-linking has no associated inflammatory response.
- Strength: Comparable strength to conventional UHMWPE products (i.e. FiberWire) for high demand applications such as RCR, M/L Instability, etc.)
- Versatile: RFR 1.5mm & 2.5mm, #2 RND, 2-0 RND



Product attributes are highly tuneable based % and size of collagen fiber

MICROBRAID Bench Data



Human mesenchymal cell proliferation over 14 days

MICROBRAID significantly higher cell attachment capacity compared to collagen coated FiberWire

MICROBRAID facilitates cell attachment and proliferation



Focus on Clinical Data Generation

Generate clinical data and long-term evidence

- Use 2021 to create clinical case series data demonstrating value across a breadth of indications:
  - Subscapularis (TSA) – Completed Q4 2021
  - Gluteus Medius Hip – Underway at OSU, Data Q1 2022
  - Foot & Ankle – Protocol in place, Data Q1 2022
- Multi-Ctr Subscapularis Registry underway. 5 sites
- Launch patient registry for Tapestry RC clearance to collect long-term efficacy data which will drive 2024/2025 revenue growth.
- Expand patient registry approach to include Subscapularis (TSA) and Hip Capsule.
- Position ourselves for long-term success with a portfolio of evidence.

TAPESTRY® Bioengineered Organized Collagen Based Microfibers for Tendon Regeneration

Introduction

Materials and Methods

Embody Highlights

Growing and Attractive Market	• Targeting high growth Orthopedics applications for collagen value proposition • Substantially de-risked with 500+ Tapestry Patients • FDA 510(k) Clearance of Tapestry RC System in Q2 2022 • MICROBRAID™ Suture FDA 510(k) clearance in Q1 2023
Novel next-generation regenerative material platform	• Robust IP Portfolio with protection of surgical implants and proprietary components formulation together with state-of-the-art production techniques • 9 US Patents, 18 Patent Families & 27 Pending Applications • Favorable COGs, 80%+ GM and a scalable manufacturing facility • Scalable platform technology across Sports Medicine
Seasoned and experienced team	• Extensive orthopedic, device and biomaterials experience • Successfully lead, commercialized and exited new technologies • Strong Scientific and Clinical Advisor engagement